How does Pompe disease present in adults?

Late-onset Pompe disease typically presents with proximal limb-girdle weakness, respiratory failure (often nocturnal), and may mimic limb-girdle muscular dystrophy.

What FVC decline warrants respiratory support?

FVC 10% per year indicates need for nocturnal non-invasive ventilation consideration.

How is enzyme replacement therapy efficacy monitored?

Key outcomes include stabilization or improvement in FVC%, 6-minute walk test distance, and muscle strength measured by MRC scale.

What is the GAA gene testing significance?

GAA mutations confirm the diagnosis; c.-32-13T>G (IVS1) splice site variant is common in late-onset, while infantile-onset typically has null mutations.

When should respiratory support be initiated?

Nocturnal BiPAP should be considered when FVC is 10% below upright measurement.

Pompe Disease Progression Assessment

Evaluates Pompe disease (glycogen storage disease type II) progression using respiratory function (FVC% predicted), muscle strength testing, and walking distance to guide enzyme replacement therapy decisions.

Use the full interactive calculator below, or

Related Calculators

Fabry Severity

Medical Calculators

ALSFRS-R

Medical Calculators

HD Burden Score

Medical Calculators

Pompe Disease Progression Assessment

Related Calculators

Frequently Asked Questions

How does Pompe disease present in adults?

What FVC decline warrants respiratory support?

How is enzyme replacement therapy efficacy monitored?

What is the GAA gene testing significance?

When should respiratory support be initiated?